SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19 individuals.
COVID-19
Cellular immune response
Immunology
MHC class 1
T cells
Journal
The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877
Informations de publication
Date de publication:
01 03 2021
01 03 2021
Historique:
received:
26
10
2020
accepted:
07
01
2021
pubmed:
12
1
2021
medline:
9
3
2021
entrez:
11
1
2021
Statut:
ppublish
Résumé
Characterization of the T cell response in individuals who recover from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is critical to understanding its contribution to protective immunity. A multiplexed peptide-MHC tetramer approach was used to screen 408 SARS-CoV-2 candidate epitopes for CD8+ T cell recognition in a cross-sectional sample of 30 coronavirus disease 2019 convalescent individuals. T cells were evaluated using a 28-marker phenotypic panel, and findings were modelled against time from diagnosis and from humoral and inflammatory responses. There were 132 SARS-CoV-2-specific CD8+ T cell responses detected across 6 different HLAs, corresponding to 52 unique epitope reactivities. CD8+ T cell responses were detected in almost all convalescent individuals and were directed against several structural and nonstructural target epitopes from the entire SARS-CoV-2 proteome. A unique phenotype for SARS-CoV-2-specific T cells was observed that was distinct from other common virus-specific T cells detected in the same cross-sectional sample and characterized by early differentiation kinetics. Modelling demonstrated a coordinated and dynamic immune response characterized by a decrease in inflammation, increase in neutralizing antibody titer, and differentiation of a specific CD8+ T cell response. Overall, T cells exhibited distinct differentiation into stem cell and transitional memory states (subsets), which may be key to developing durable protection.
Identifiants
pubmed: 33427749
pii: 145476
doi: 10.1172/JCI145476
pmc: PMC7919723
doi:
pii:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
HLA Antigens
0
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : R01 AI152078
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI120938
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL059842
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI052733
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI128779
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL151826
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI102623
Pays : United States
Organisme : NINR NIH HHS
ID : R01 NR005228
Pays : United States
Références
Science. 2009 Jun 19;324(5934):1569-72
pubmed: 19423777
Sci Immunol. 2017 Jun 2;2(12):
pubmed: 28783656
Eur J Immunol. 2013 Nov;43(11):2797-809
pubmed: 24258910
Cell Rep Med. 2020 Sep 22;1(6):100081
pubmed: 32839763
Science. 2020 Aug 14;369(6505):806-811
pubmed: 32434945
Nat Commun. 2018 Jul 26;9(1):3000
pubmed: 30050138
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
J Clin Invest. 2020 Jun 1;130(6):2757-2765
pubmed: 32254064
J Clin Microbiol. 2021 Jan 21;59(2):
pubmed: 33139419
Immunity. 2020 Nov 17;53(5):1095-1107.e3
pubmed: 33128877
PLoS Pathog. 2013;9(6):e1003422
pubmed: 23818845
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
J Immunother Cancer. 2019 Sep 12;7(1):249
pubmed: 31511069
Sci Rep. 2020 Nov 24;10(1):20465
pubmed: 33235258
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Nat Biotechnol. 2013 Jul;31(7):623-9
pubmed: 23748502
J Infect Dis. 2020 Nov 13;222(12):1974-1984
pubmed: 32910175
Nat Med. 2021 Jan;27(1):78-85
pubmed: 33184509
J Exp Med. 1999 Sep 6;190(5):705-15
pubmed: 10477554
Nat Biotechnol. 2018 Dec 03;:
pubmed: 30531897
Nature. 2020 Nov;587(7833):270-274
pubmed: 32726801
Cytometry A. 2013 May;83(5):483-94
pubmed: 23512433
Lancet. 2020 Jun 13;395(10240):1845-1854
pubmed: 32450106
Cell Host Microbe. 2020 Apr 8;27(4):671-680.e2
pubmed: 32183941
Front Immunol. 2020 May 01;11:827
pubmed: 32425950
J Clin Invest. 2020 Nov 2;130(11):6141-6150
pubmed: 32764200
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Nat Immunol. 2020 Nov;21(11):1336-1345
pubmed: 32887977
Open Forum Infect Dis. 2020 Nov 26;8(2):ofaa574
pubmed: 33553467
Immunity. 2020 Dec 15;53(6):1245-1257.e5
pubmed: 33326767
Immunity. 2020 Jun 16;52(6):971-977.e3
pubmed: 32413330